A phase 3, randomized, double-blind trial to evaluate the safety of a 20-valent pneumococcal conjugate vaccine in healthy infants at investigator sites in the United States and potentially other countries to be determined. This study is part of the Phase 3 clinical development program to support the use of 20vPnC in the pediatric population. The purpose of this study is to describe the safety of 20vPnC.

Register Today!.

Trial Information

Start DateTBD
End DateTBD
Trial DurationTBD
Number of VisitsTBD
Lead CRCAdam Pawluch
StatusUpcoming Trial

For additional information
on this trial contact:

Phone705-566-0005